ClinicalTrials.gg
RecruitingNCT0739580423146Updated May 29, 2026

How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

An observational study in Metastatic Hormone-sensitive Prostate Cancer (mHSPC), sponsored by Bayer. Recruiting at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Prostatic Neoplasms by Bayer — 11 open to participants now, 16 under way, 1 of them phase 3. Prostatic Neoplasms · Bayer.

Planned enrollment
24th of 40
500 · median 700
Started
2026
with 5 others
Observational
40 of 75
8 open now
Primary completion
2031-02
later than 14 of 15 live
Registered
71st of 75
by date

Among the 75 studies in Prostatic Neoplasms by Bayer, this one is the 24th largest by planned enrollment of the 40 observational ones that give a count, is one of 6 that started in 2026, is one of 40 observational ones, reaches primary completion later than 14 of the 15 other live ones, and was the 71st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

11 of the 75 studies in Prostatic Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Prostatic Neoplasms by Bayer, or all of them as a file.
02

Study summary

Prostate cancer is a disease where cells in the prostate gland grow out of control. When prostate cancer has spread to other parts of the body but still responds to hormone treatment, it is called metastatic hormone-sensitive prostate cancer (mHSPC).

The usual treatment for this stage of prostate cancer is hormone therapy (called androgen-deprivation therapy or ADT) combined with another medicine that blocks the effect of male hormones on cancer cells, known as an androgen-receptor pathway inhibitor. Darolutamide is a newer type of androgen-receptor inhibitor.

The main goal of this study is to find out how well a combination of two treatments-darolutamide and hormone therapy (also called androgen-deprivation therapy or ADT)-works for men in Germany who have advanced prostate cancer that has spread to other parts of the body and still responds to hormone treatment. The study will look at how many men have very low or undetectable levels of a protein called prostate-specific antigen (PSA) in their blood after 12 months of treatment. PSA is a marker that doctors use to check how active prostate cancer is.

The study will also look at how long men live after starting this treatment, and will collect information about their health, the type of prostate cancer they have, and any other medicines they are taking. The study will last for 5 years. At the start of the study, the study doctor will collect information about each patient's background, such as age, other health problems, and details about their prostate cancer. This information will be taken from the patient's medical records if available. If some information is missing, the doctor may ask the patient directly.

Other information will be collected as the study goes on. This includes details about the patient's treatment, how they are doing during their regular medical visits, and any changes in their health. These check-ups and data collection will happen as part of the patient's usual care, including at the beginning of treatment, during treatment visits, follow-up visits, and at the end of the study observation period.

03

Conditions studied

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men with metastatic hormone-sensitive mHSPC fulfilling the inclusion and exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged ≥ 18 years
  • Diagnosis of mHSPC with histological or cytological evidence for adenocarcinoma of prostate
  • disease by conventional or new generation imaging

    • Physician decision to initiate treatment with Darolutamide+ADT was made as per investigator's routine treatment practice prior to enrollment in the study
    • Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).

Exclusion criteria

Exclusion Criteria:

  • Darolutamide treatment started more than 30 days prior to study enrollment
  • ADT treatment started more than 12 weeks before the start of treatment with darolutamide plus ADT
  • to darolutamide or any other
  • Other prior systemic hormonal or anti-cancer treatment for mHSPC
  • Participation in an program for prostate cancer with interventions outside of routine clinical practice
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Men with mHSPC fulfilling the inclusion and exclusion criteria

    Drug: darolutamide plus ADT treatment

Interventions

  • Drugdarolutamide plus ADT treatment

    2\*300 mg darolutamide twice daily + ADT treatment

06

What researchers measure

Primary outcomes

  1. Number of participants with PSA < 0.2 ng/mL

    Time frame: 12 months

Secondary outcomes

  1. Number of deaths or participants with end of observation

    Time frame: up to 60 months

  2. Number of participants with PSA < 0.2 ng/mL

    Time frame: 3, 6, and 9 months

  3. Number of participants with certain demographic characteristics

    * age * race

    Time frame: at study start

  4. Number of participants with certain clinical characteristics

    * comorbities * Gleason score/ISUP * PSA prior therapy * prostate cancer volume and risk * type of metastatic disease * ECOG performance

    Time frame: at study start

  5. Number of participants with certain testosterone value

    Time frame: at study start

  6. Duration of Darolutamide+ADT treatment

    Time frame: up to 60 months

  7. Timing of Darolutamide+ADT treatment start

    Time frame: up to 60 months

  8. Kind of ADT treatment

    Time frame: up to 60 months

  9. Number of participants who change ADT treatment

    Time frame: up to 60 months

  10. Number of participants who change dosage of Darolutamide treatment

    Time frame: up to 60 months

  11. Number of participants with certain reasons for darolutamide plus ADT treatment discontinuation

    Time frame: up to 60 months

  12. Number of participants with certain subsequent anti-cancer therapies

    Time frame: up to 60 months

  13. Number of participants with treatment-emergent adverse events

    Time frame: from start of treatment up to 60 months

  14. Number of participants with certain concomitant medication at study start and changes during treatment with darolutamide plus ADT

    Time frame: up to 60 months

07

Study locations

1 of 1 sites recruiting
  • Many
    Locations, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2031, 58 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 58 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Feb 15, 2031
CompletionEst.
Feb 15, 2031
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395804
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Apr 14, 2026
Primary completion
Feb 15, 2031 (estimated)
Completion
Feb 15, 2031 (estimated)
Last update
May 29, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion